Early Response, Sustained Control: 52-Week Outcomes With Remibrutinib

Nicholas Brownstone, MD, takes a closer look at what disease activity actually does over time in chronic spontaneous urticaria (CSU), drawing on two Phase 3 analyses from the REMIX-1 and REMIX-2 program. Rather than focusing on a single endpoint, he walks through patient-level shifts in UAS7 disease activity bands, tracing how patients moved from severe or moderate disease toward well-controlled states and complete response across 52 weeks of treatment with remibrutinib. The video highlights how quickly these changes emerged, often within the first week, and how they were sustained through the open-label extension, including among patients who initially received placebo and later transitioned to active therapy. Together, the data offer a clinically grounded view of response durability, variability, and real-world relevance for an oral BTK inhibitor in patients with CSU who remain symptomatic despite second-generation H1 antihistamines.